NBIX
Neurocrine Biosciences Inc
$138.00
0.00 (0.00%) Today
0.35 (0.25%) Pre-market
— up— down
Market Cap
$14.06B-1.4%
Revenue (TTM)
$3.26B+34.4%
Net Income (TTM)
$685.90M+101.3%
EPS (TTM)
6.82+101.3%
Shares Out
100.55M
100.55MP/E Ratio
19.71
19.71Forward P/E
15.58
15.58Open
$138.35
$138.35Previous Close
$138.35
$138.35Day Range
$136.31 – $141.07
$136.31 – $141.0752-Week Range
$122.14 – $186.12
$122.14 – $186.12Beta
0.37
0.37Volume
1.49M
1.49MAvg Volume
1.23M
1.23MAnalyst Rating
Buy
BuyExchange
NASDAQ NMS - GLOBAL MARKET
NASDAQ NMS - GLOBAL MARKETAbout NBIX
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).